C en Junda is a highly successful investor in China's pharmaceutical sector, deriving his wealth from strategic early stakes in two industry giants: Jiangsu Hengrui Medicine and Hansoh Pharmaceutical Group. He holds degrees from Zhejiang University and the China State Institute of Pharmaceutical Industry, giving him the technical background to identify promising healthcare ventures. His investment philosophy aligned closely with the rise of Sun Piaoyang and Zhong Huijuan, the husband-and-wife team behind Hengrui and Hansoh, respectively.

While not involved in the day-to-day management of these companies, Cen's long-term holdings have generated immense value as both firms grew to dominate the Chinese market for oncology and psychotropic drugs. His fortune was notably solidified when Hansoh Pharmaceutical went public in Hong Kong. He is often cited as a prime example of an investor who leveraged deep industry knowledge to back the right founders during the formative years of China's modern biotech industry.

Quick Reads:

• Early investor in Jiangsu Hengrui Medicine and Hansoh Pharmaceutical.
• Long-term business associate of pharma tycoons Sun Piaoyang and Zhong Huijuan.
• Holds a degree from Zhejiang University.
• His wealth surged following Hansoh's IPO in Hong Kong.
• Resides in Lianyungang, a hub for China's pharmaceutical industry.